Jeffrey Eisele
CIK 1827326 · Chief Development Officer · last filed 2025-01-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
APLS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
100 5TH AVENUE, 3RD FLOOR
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Development Officer | 55,312 | $41.03 | $2.27M | -$1.49M | 24 | 2025-01-30 |
Recent Filings · Page 2 of 4
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-29 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −279 | -$17.9K | EDGAR |
| 2024-01-24 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −7,378 | -$469.9K | EDGAR |
| 2024-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −7,378 | -$469.9K | EDGAR |
| 2024-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,607 | -$104.4K | EDGAR |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −1,607 | -$104.4K | EDGAR |
| 2024-01-18 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −5,207 | -$341.5K | EDGAR |
| 2024-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −5,207 | -$341.5K | EDGAR |
| 2024-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +19,070 | -$29.3K | EDGAR |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −438 | -$29.3K | EDGAR |
| 2023-12-28 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −303 | -$18.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.